# Polymeric Nanoparticles--Tools in a Drug Delivery System in Selected Cancer Therapies
## 5 Polymeric Nanoparticles in Breast and Ovarian Therapy  
Undoubtedly, the most common type of cancer occurring in women is breast cancer [61; 62; 63]. Among the different types, triple-negative breast cancer (TNBC) appears to be the most malignant and most metastatic [61]. For therapy, the use of combinations of various taxanes, i.e., PTX or DTX, platinum-based compounds, e.g., cisplatin, or the application of drugs from the anthracycline group, is common, with doxorubicin leading the way [61; 62]. The second type of cancer closely related to breast cancer is ovarian cancer [64]. The division of ovarian cancer is based on histopathological changes within the epithelium and includes five subtypes, 90% of which are high-grade serous carcinoma [64; 65]. Treatment of ovarian cancer is based on a combination of surgical resection and chemotherapy [66]. The gold standard is the administration of platinum-based drugs, e.g., carboplatin, whose efficacy reaches up to 80% in combination with PTX. However, this treatment is not always sufficient, as recurrence of the disease is observed [66]. \begin{table}
\begin{tabular}{c c c c c c c} \hline \hline
**PNPs** & **Formulation Method** & **Size (nm)** & **Drug** & **Dose** & **In Vitro/In Vivo** & **Ref.** \\ \hline PHBV/PLGA & Double emulsion solvent evaporation & \(\sim\)150 & 5-FU & 3 mg/mL In vitro—HT-29, CT-26 In vivo—BALB/c mice & [44] \\ PLGA-PEG-PLGA & Double emulsion solvent evaporation & \(\sim\)40 & 5-FU/Chrysin & 10 mg/mL In vitro—HT-29 & [45] \\ HPMC phthalate & Nanoprecipitation & \(\sim\)478 & Doxycycline & 5 mg/kg, 10 mg/kg & In vivo—Swiss albino mice & [46] \\ D,L-PLGA & Single emulsion solvent evaporation & \(\sim\)191 & Curcumin & 10 mg, 20 mg In vitro—HT-29 & [47] \\ D,L-PLGA & Spontaneous emulsification & \(\sim\)310 & SN-38 & 15 mg In vitro—COLO-205 & [48] \\ Poly-UA & Nanoprecipitation & \(\sim\)171 & Mith-A & 3 mg In vitro—ST-26 In vitro—BALB/c mice & [49] \\ Chitosan polymeric & Ionic gelation technique & \(\sim\)200 & Imatinib & 5 mg In vitro—ST-26 In vitro—Wistar rat & [50] \\ D,L-PLGA-PEG- & Double emulsion & \(\sim\)201 & Oxaliplatin & 5 mg/kg In vitro—ST-26 In vitro—BALB/c mice & [51] \\ FA & solvent evaporation & \(\sim\)237 & Quercetin and CAPE & 5 mg and 15 mg In vitro—HT-29 & [52] \\ D,L-PLGA & Single emulsion solvent evaporation & \(\sim\)345 & Bevacizumabab & 25 mg/mL CD44 std and CD4v6+ & [53] \\ v6 Fab-PLGA-PEG & Double emulsion solvent evaporation & \(\sim\)289 & Camptothecin & 6 mg In vitro—ST-26 In vivo—BALB/c mice & [25; 54] \\ CS-Chitosanan & Single emulsion solvent evaporation & \(\sim\)154 & Benzimidazole & 0.0125 mg/25 mL In vitro—HT-29 & [55] \\ PMMA & Single emulsion solvent evaporation & \(\sim\)114 & PTX and DHA & 6 mg/mL In vitro—HT-29 & [56] \\ PEG & Single emulsion solvent evaporation & \(\sim\)114 & PTX and DHA & 6 mg/mL In vitro—HT-29 & [56] \\ PCL-PEG-PCL & Double emulsion solvent evaporation & \(\sim\)95 & Cur and MTX & 4 mg and 2 mg SW1417 & [57] \\ D,L-PLGA & Modified salting-out Double emulsion solvent evaporation & \(\sim\)200 & Meloxicam & n/d In vitro—HT-29 & [28] \\ PEG-PLGA & Double emulsion solvent evaporation & \(\sim\)147 & PTX & 1 mg In vitro—S174T, COLO205, HCT116 & [58] \\ PEG-PLGA & Double emulsion solvent evaporation & \(\sim\)289 & Sorafenib and PEDF & 2 mg and 25 mg In vivo—C26 In vitro—BALB/c mice & [59; 60] \\ \hline  & PHBV—poly(3-hydroxybutyrate-co-3-hydroxyvalerate); D,L-PLGA—poly(0,L-lactate-oc-glycolide); 5-FU—5, fluorouracil; PEG—polyethylene glycol; HPMC—hydroxypropyl methyl cellulose; SN-38—7 ethyl-10-hydroxy-carbothecin; EGFR—epidermal growth factor receptor; mAb—monoclonal antibody; poly-UA—poly(ursolic acid); Mith-A—mithamycin-A; FA—foliic acid; CAPE—caffei-acid phenethyl ester; Fab—antibody fragment; CS—chondroitin sulfate; PMMA—poly(methyl methacrylate); PTX—paclitaxel; DHA—dilhydroartemisinin; Cur–curcurcum; MTX—methotrexate; PAA—poly(acrylic acid); \(\varepsilon\)-PCL—poly(\(\varepsilon\)-caprolactone); PEDF—pigent epithelium-derived factor. \\ \hline \hline \end{tabular}
\end{table}